(HealthDay News) — In a clinical practice guideline issued by the American Society for Radiation Oncology and published online in Practical Radiation Oncology, evidence-based recommendations are ...

"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD. The pCR was 37.3% (95% ...

After hours: March 18 at 5:46:11 PM EDT Loading Chart for RFL ...

Low grade non-muscle invasive bladder cancer (Ta) confirmed by cystoscopy and cold cup biopsy of the visualized tumor at screening or within 8 weeks before screening Negative voiding cytology for high ...

Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies. For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover ...